Approximately 15% of sporadic breast cancers are characterized by this phenotype [37], but this particular cluster additionally possesses the dominant characteristics of aggressive breast cancers that are insensitive to both hormone therapy and trastuzumab (Herceptin, Genentech) [38], a humanized monoclonal antibody directed against ERBB2. This evidence concerns the gene ERBB2 and breast carcinoma.